Sox, after rereading Leo's 9/19 PR, I am convinced that Leo's target audience for the PR was not shareholders, but the larger healthcare community and the general public. After the intro paragraph look at the first sentence of the remaining 4 paragraphs:
1. Cellceutix may have one of the world’s best technologies for combating antibiotic resistant bacteria in its novel class of antibiotics called defensin mimetics.
2. The public is aware of the Ebola virus threat, but may not be as aware of today’s deadly bacteria.
3. Cellceutix in approximately one and a half months expects to have have top-line data from its Phase 2b trial of its antibiotic Brilacidin for Acute Bacterial Skin and Skin Structure Infections.
4. “If we achieve successful data from the recently completed Phase 2 trial, my hope is that people will understand the defensin mimetic’s potential.
Many, if not most, of CTIX shareholders (especially the longs) are very much aware of all this and, perhaps, is the reason the PR has been characterized as "fluff and blather." While this PR was emailed to shareholders, I believe Leo's intent was to communicate with larger outside audiences that may have little knowledge of CTIX and its antibiotic platform and to connect the company to a presidential "call-to-action" that could likely mean wider dissemination of Leo's message to the targeted audiences.
Yes the email was sent to us, but, no, I don't think it was, primarily, meant for us.
AI
Market Data 
Markets 
